Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

Ítems similars

• Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
  per: Mickisch, G, et al.
  Publicat: (2010)
• Regarding: ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’
  per: Porta, C
  Publicat: (2010)
• Comment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’
  per: Charbonneau, C, et al.
  Publicat: (2010)
• Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy
  per: Mickisch, Gerald HJ, et al.
  Publicat: (2011)
• Bevacizumab Wins Cost-Effectiveness Contest in First-Line Metastatic Colorectal Cancer
  Publicat: (2015)